We aimed to develop an efficient, flexible, scalable and evidence-based approach to sequencebased diagnostic analysis/re-analysis of conditions with very large numbers of different causative genes. We then wished to define the expected rate of plausibly causative variants coming through strict filtering in control in comparison to disease populations to quantify background diagnostic "noise".
Introduction
The analysis of genomic sequence and copy number is now in widespread use as a first-line investigation in the diagnosis of Mendelian disease. In addition to an obvious role in genetic counselling, diagnostic genetic testing can also help avoid invasive procedures (e.g. muscle biopsy in Duchenne and Becker muscular dystrophy 1 ) and reduce the length of time required to come to a definitive diagnosis (e.g. leukodystrophies 2 ). Such testing has historically been restricted to individuals with distinctive clinical presentations and/or suggestive family histories, which significantly increase the prior probability of specific genetic pathology. However, it is now possible to perform comprehensive analysis of the protein coding region (whole exome sequencing (WES) [3] [4] [5] or the entirety of the human genome (whole genome sequencing (WGS) 6,7 ) for clinical diagnostic purposes at reasonable cost. Although this represents an exciting opportunity, the number of variants passing any diagnostic filter is strongly correlated with total genomic space sampled. The more genetically heterogenous a disease, the more causal genes are individually implicated and hence the more variants are likely to become diagnostic candidates. It is thus important to develop strategies that can define the impact of increasing the number of variants on false positive and false negative errors in diagnostic assignments; both may result in significant harm through misdiagnosis and missed diagnoses and certainly increase the workload for clinical scientists and clinicians.
The diagnostic filtering of previously unclassified variants is most commonly based on minor allele frequency (MAF) and mutational consequence. The effectiveness of the former has been revolutionized by the availability of data from the Exome Aggregation Consortium (ExAC) 8 
and the
Genome Aggregation Database (gnomAD; http://gnomad.broadinstitute.org). These resources provide access to technically robust variant calls from diverse populations of known providence. There are many different publicly available tools for defining the consequence of an individual variant call 9 . One of the most widely used is the Ensembl Variant Effect Predictor (VEP) 10 . VEP predicts the effect of each alternative allele on each overlapping transcript for a variant and assigns Sequence Ontology 11 terms to describe the consequences. It can be run either online or using a locally installed version of the program. VEP exploits the extensive and regularly updated Ensembl datasets to provide the most comprehensive variant annotation possible in coding and non-coding regions. It also allows extensibility through the 'plugin' system which allows custom methods to be easily added.
Automated variant annotation and filtering of WES data using the Ensembl VEP has been successfully applied in a genetically heterogeneous disease cohort by the Deciphering Developmental Disorders Study (DDD) 12, 13 . The DDD Study has recruited >13,400 individuals, with previously undiagnosed severe and/or extreme developmental disorders (DD), from the UK and the Republic of Ireland. The principal aim of the project is to define the genetic architecture of DD using trio-based WES analyses as the main analytical tool 14 . Important secondary aims were to identify novel DD loci and develop diagnostic approaches that could be translated into clinical practice. To facilitate this, we developed a database of all known causative DD loci (DDG2P) that was structured to allow facile, very high throughput filtering of variant calls. This dataset has been used in each of the DDD flagship papers 12, 13 . The continual updating of DDG2P has been one of the main drivers of the improvement in diagnostic rates through iterative reporting of the same data 15 . The basic architecture and processes used to populate DDG2P 16 have been adapted to be applicable to any clinical presentation that has a reasonable prior probability of being caused by highly-penetrant genotypes at a defined group of loci.
To expand from DD to other clinical presentations and to create a system that could be maintained and updated by multiple curators, we created the genotype-to-phenotype (G2P) online system with an associated web application to hosts the DDG2P database and any similar datasets.
Here we describe G2P, tailored to address the problem of robust, efficient and flexible prioritization of genotypes identified from NGS data to aid the diagnosis of genetic disease. As part of our G2P system, we have developed a suite of tools and resources: 1. The G2P portal/web-application which is freely available at https://www.ebi.ac.uk/gene2phenotype/ for creation, curation and dissemination of G2P datasets; 2. G2P datasets which formalize collections of locus-genotypemechanism-disease-evidence threads (LGMDET), curated from the literature, and found to be implicated in the cause of a specific disease or clinical presentation; 3. The G2P extension to Ensembl VEP which is freely available at https://www.ebi.ac.uk/gene2phenotype/g2p_vep_plugin (VEP-G2P).
VEP-G2P utilizes the allelic requirement information from G2P datasets/panels and leverages allele frequency data from public datasets such as Genome Aggregation Database (gnomAD) together with the mutational consequence annotations from VEP to produce list of potentially causative genotype(s)
given an individual's VCF file as an input. We also present an estimation of false positive and false negative rates associated with its application to WES datasets.
RESULTS

G2P data structure, web development and curation interface
The structure of G2P datasets is based on that of the DDG2P diagnostic tool which has been previously described 17 (Figure 1A ; Online-only supplemental material). In G2P, each dataset is focused on a disease grouping or defined category of clinical presentation that is of relevance to the clinical diagnosis of Mendelian disease. For a dataset to be publicly released it must be comprehensive, up-to-date and have a plan for future active curation. Each entry in each dataset links a gene or locus, via a disease mechanism, to a disease. A disease mechanism is defined as both an allelic requirement (mode of inheritance, for example biallelic or monoallelic) and a mutation consequence (mode of pathogenicity, for example activating or loss of function). A confidence attribute -confirmed, probable or possible -is assigned to indicate how likely it is that the gene is implicated in the cause of disease; only confirmed and probable categories are reportable for clinical diagnosis. A fourth category ("both RD and IF") has been included to highlight for clinical review genotypes that are plausibly associated with both the relevant disease (RD) and another disease that represents an incidental finding (IF). For example, biallelic mutations in BRCA2 cause a developmental disorder (Fanconi Anaemia) but will also define a cancer predisposition for both parents of the affected individual.
To ensure consistency in development and curation, the rules used to assign confidence, allelic requirement and mutation consequence to entries, are defined and available via the web application in the form of tables (Tables S1-3). We store the links to the publications (via PMID) that provide evidence for that specific gene-disease thread. The locus-genotype-mechanism-disease-evidence link is further characterized by coding the organ specificity and linking to a set of phenotype terms from the Human Phenotype Ontology (HPO) 17 . These data are all accessible via the G2P web application, which is searchable by gene symbol, disease name or disease ontology term. The released datasets are downloadable as CSV files (https://www.ebi.ac.uk/gene2phenotype/downloads).
Locus-genotype-mechanism-disease-evidence threads (LGMDET)
Here we present details of the two currently available G2P datasets: G2P DD and G2P Cancer (Table S4 severe and/or extreme disorders that plausibly have their genesis during embryogenesis or early fetal brain developments. This dataset was populated by a combination of clinical knowledge, systematic literature review and genes from existing in-house gene panels by two consultant clinical geneticists (DRF and HVF). We chose to exclude two major groups of developmental disease -isolated hearing loss and isolated dental anomalies -which are planned to have their own G2P panels and (excepting composite phenotypes) are unlikely to present as undiagnosed developmental disorders. G2P Cancer aims to identify Mendelian cancer susceptibility in individuals affected with cancer or with a strong family history.
The characteristics of the 2044 G2P DD and 123 G2P Cancer reportable (i.e. confirmed, probable,
RD&IF)
LGMDET entries are summarized in Table 1 .
VEP-G2P plugin
The VEP-G2P plugin is designed to work with any G2P panel to identify plausibly diseasecausing variants from WES or WGS data (VCF files); it enables the facile and flexible integration of allele frequency data in addition to mutation consequence. The default predictions and annotations are invaluable for filtering variants to find those relevant for further analysis based on consequence type and allele frequencies. The VEP-G2P plugin uses the default annotations, the individual's genotype information and knowledge from the G2P datasets to find genes which have a sufficient number of potentially deleterious variants according to their allelic requirements and are therefore likely disease causing (Figure 1 ; Online-only supplemental material).
Comparing VEP-G2P outputs from different cohorts
To evaluate the performance of VEP-G2P plugin we analyzed three independent sets of WES data, each of which had undergone extensive prior analysis. The plugin was run using a local VEP installation, and details of the technical aspects of each exome collection are given in Table 2 . It should be noted that due to differences in the upstream variant calling pipelines ( Table 2; data also processed at different times at different centres), there is a slight excess in the number of filtered and unfiltered indel and SNVs per sample in the DDD cohort compared to the colorectal cancer (CRC) and
Generation Scotland (GS) 18 cohorts (Table S6 ). Although it would be possible to realign and recall these datasets to ensure consistency, we chose to proceed without trying to resolve these differences as this is representative of "real life" data available to most research groups involved in clinical diagnostic research.
Discriminative diagnostic indicators
To look for characteristics that may discriminate diagnostic from background genomic variants, we compared the VEP-G2P filtered output of each panel applied to different WES cohorts:
The G2P panel with its target disease cohort (i.e. VEP-G2P DD with DDD cohort; VEP-G2P Cancer with CRC cohort), a G2P panel with a discrepant disease cohort (VEP-G2P DD with CRC cohort) and G2P panels with the controls (VEP-G2P DD with GS; VEP-G2P Cancer with GS). The ethical approval and consent procedures governing the recruitment to the DDD Study allow diagnostic analyses only for the identification of pertinent genetic results. It specifically prohibits the intentional identification of "incidental findings", such as genotypes related to adult-onset cancer susceptibility; for this reason, we did not apply filtering using VEP-G2P Cancer with the DDD cohort.
For VEP-G2P DD the proportion of SNV that survived filtering was 1 in 31.4K in the DDD cohort and 1:44.3K in GS (Table S6 ; p = 6.56E-13). The rate in the CRC cohort using VEP-G2P DD was similar to the control group at 1 in 40.8K (Table S6 ; p = 0.16 cf GS). Comparing the results from the DDD cohort with GS controls there is a significant excess of loss-of-function and missense variants for monoallelic and biallelic genes. A higher proportion of the surviving variants in monoallelic genes were missense variants in GS compared to DDD (83.7% cf 64.9%) (Figure 2A,B ; Tables S7,S8 ). The missense variants that survived filtering in DDD had a higher proportion with a CADD 19 score >30 compared to GS (11.4% cf 7.6%; ) ( Figure 2D) . The mean MAF of all missense variants in GS was 1.68x higher than in DDD for monoallelic genes and 1.24x for biallelic genes. For loss-of-function variants the MAF was 2.0-3.5x higher in GS. 115/454 (25.3%) monoallelic DDG2P genes reported had a higher proportion of individuals with variants in GS compared to the DDD WES (Table S13) while 224/454 (49.3%) had no reported variants in GS. The respective proportions for biallelic DDG2P genes are 63/676 (9.3%) and 4/676 (0.6%) (Tables S13).
Using G2P Cancer in the CRC cohort compared to GS revealed no significant enrichment in any class of variant (Figure 2A,B) . However, monoallelic G2P Cancer LGMDET stop-gained variants in GS had a MAF 2.67x higher than those in CRC (Table S11 ). For biallelic G2P Cancer LGMDET, no variants survived filtering in GS with 9 reported in the CRC WES (Table S12 ). 25/61 of all genes reported by the VEP-G2P plugin were found in a higher proportion of individuals in GS than CRC with 22/61 being exclusively reported in CRC (Table S14 ). Table S6 ). The distribution of the numbers of variants reported per individual is shifted to the right in DDD probands compared to individuals in GS (Figure 2C) .
With a significantly smaller proportion of DDD probands have no variants reported compared to both GS individuals (p = 7.9e-09) and CRC probands (p = 2.3e-12). However, these differences could, at least in part, be systematic and reflect the alignment/variant calling, read depth or targeted pull-down used in each analysis ( Table 2 ) rather than any underlying differences in biology of the populations.
Analysis of larger control cohorts that have been processed using the same pipelines as the case cohort and the variants jointly called will be required to determine if these differences are real.
Using data from the first 4293 trio WES in the DDD study the over-representation of plausibly deleterious de novo variants in 94 different genes achieved genome-wide significance 12 . There was a total of 804 likely causative de novo variants in these 94 genes that were reported to referring clinicians. Proband-only analysis using VEP-G2P with DDG2P LGMDETs (VEP-G2P DD ) successfully identified 782 (97.3%) of the reported variants. These 782 variants were amongst the 2342 variants that survived filtering, giving a precision of 33.4% and a false positive rate of 66.6%. Of the 22 de novo mutations that were missed, the most common reason was that they had a MAF that was higher than the 1:10000 cut-off used in our monoallelic filtering (Figure 3A) .
To assess the performance of VEP-G2P DD in identifying inherited causative variants, we used the recent comprehensive re-analysis of known diagnoses in the first 1133 trios in DDD 16 excluding reported de novo mutations. This method successfully identified 124 of the 152 known diagnostic inherited variants, giving a sensitivity of 81.6% with a precision of 22.7%. The reasons for "missed" diagnoses were similar to those for de novo mutations (Figure 3B) .
Receiver operating characteristics (ROC) analysis has proven to be a highly effective method of comparing the performance of diagnostic tests. The most common form of ROC space analysis uses a continuous variable to create a ROC curve -the larger the area under this curve (AUC) the "better" the test. We wished to explore how VEP-G2P DD performed in ROC space. We therefore chose to use the set of 1700 de novo mutations which occurred in DDD probands within genes that were monoallelic and reportable in G2P DD . The only continuous variable that is available to us was the MAF and given that our filter cutoff is 1:10,000 and many variants are unique (having no computationally useful MAF) the area of ROC space that can be interrogated using this approach is very small. However we can calculate the lower bound for AUC of 0.964 using the simple approach developed for binary tests 20 ([sensitivity + specificity]/2) using VEP-G2P default parameters.
It has been noted recently that ROC curve analysis can be misleading when using binary classifiers 21 and that precision-recall curves may be used in conjunction with ROC curves to provide a more realistic picture of the tests under investigation. The precision-recall plot using the same data as that used in the ROC analysis does indeed show the cost of increasing sensitivity with respect to precision (Figure 3B ). The variants identified for each sample were screened for quality and those with GQ < 13 (95% confidence), DP < 5 (DDD has the lowest average coverage of the three cohorts) or AD/DP < 0.2 were reset to "no-calls". Furthermore, variants with Mapping quality (MQ) < 13 (95% confidence) in DDD were also reset to "no-calls"; MQ filtering was not possible for the GS cohort (combined VCF, no MQ value available for individual calls). The variants in the cohorts' VCFs have been decomposed and normalized with VT (v0.5) prior to submission to G2P. The speed and ease of VEP-G2P plugin use has allowed us to assess the expected background output from each G2P dataset against a population ascertained dataset. This required access to WES data from individuals that have not been selected for any specific disease or clinical problem and we have used these individuals as our control group. Here we used Generation Scotland but in the near future, much larger, unselected WES and WGS control datasets will be available from UK Biobank 22 .
METHODS
W
Our analysis suggests that at least half of the variants surviving the filtering process are likely to be the result of background population genome variation rather than specifically relevant to this disease being analyzed. We consider this to be a very important "sanity check" in genetic diagnostic analysis. For this reason, we have made it very simple for any panel of any size to be converted to be compatible with VEP-G2P plugin. We have been able to implement PanelApp their origin, panels that do not show a clear difference between the output from controls and disease cohort data (using the appropriate MAF and variant consequence filters) require reassessment and/or revision prior to implementation for clinical or research use. Such analysis will be particularly useful to identify genes with a very restricted repertoire of disease-associated variants and a high background of rare high-impact variants. Such loci may be better analyzed using a variant "whitelist" approach.
Determining the "diagnostically-useful completeness" of any panel in any curation system is a major challenge; requiring balancing all possible associations of a set of comparable genotypes with the clinical presentation against the confidence that the association is causative rather than coincidental.
We have found both the statistical genomics analysis (identifying loci achieving genome-wide significance under different genetic models) and clinician case updates within DDD very helpful for DDG2P curation. However, it will be important to establish robust methods to quantitate this feature in any clinical presentation.
Family-trio WES data are hugely valuable for determining the de novo status of variants in monoallelic genes, as well as the phase of potential compound heterozygous variants in biallelic genes.
In the absence of trio data, there is a particular problem associated with accurate calling of genotypes in ultra-rare biallelic disorders as evidenced by the expected high rate of false positives which is the result of an inability to differentiate variants in cis and in trans using VEP-G2P DD for proband-only analyses,
where it is not possible to determine the phase of most variants detected within a single gene. This will be helped by longer read technology and deeper, more comprehensive data on background genetic variation in human populations. It is interesting that a significant proportion of the "missed" diagnoses in our de novo analysis were due to variants previously being assigned as causative which, on current analyses, show implausibly high MAF values.
Finally, we would like to emphasize that the VEP-G2P plugin should be considered a system for experts and it is not designed for use by laboratories or clinical services who do not have competence and experience in a multi-disciplinary approach to the diagnosis of rare genetic disease involving both scientists and clinicians. Casual use of this system could result in misdiagnosis and subsequent significant mismanagement of 'affected' individuals. These variants are at this stage computationally defined and would also normally require validation using a separate technology prior to research or clinical interpretation. Table S1 for definitions) are not reported in the pipelines used here. ***An individual gene may have more than one reportable LGMDET e.g. monoallelic/activating and biallelic/loss-of-function 
